Veröffentlichungen

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis

H. Alborzinia
A.F. Flórez
S. Kreth
L.M. Brückner
U. Yildiz
M. Gartlgruber
D.I. Odoni
G. Poschet
K. Garbowicz
C. Shao
C. Klein
J. Meier
P. Zeisberger
M. Nadler-Holly
M. Ziehm
F. Paul
J. Burhenne
E. Bell
M. Shaikhkarami
R. Würth
S.A. Stainczyk
E.M. Wecht
J. Kreth
M. Büttner
N. Ishaque
M. Schlesner
B. Nicke
C. Stresemann
M. Llamazares-Prada
J.H. Reiling
M. Fischer
I. Amit
M. Selbach
C. Herrmann
S. Wölfl
K.O. Henrich
T. Höfer
A. Trumpp
F. Westermann

Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase in B cell lymphomas

C. Lopez
N. Schleussner
S.H. Bernhart
K. Kleinheinz
S. Sungalee
H.L. Sczakiel
H. Kretzmer
U.H. Toprak
S. Glaser
R. Wagener
O. Ammerpohl
S. Bens
M. Giefing
J.C.G. Sanchez
G. Apic
D. Hubschmann
M. Janz
M. Kreuz
A. Mottok
J.M. Müller
J. Seufert
S. Hoffmann
J.O. Korbel
R.B. Russell
R. Schule
L. Trumper
W. Klapper
B. Radlwimmer
P. Lichter
R. Kuppers
M. Schlesner
S. Mathas
R. Siebert

A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior

D. Wasilewski
M. Janz
A. Koch
A. Rosenwald
U. Keller
P. Vajkoczy
K. Faust
I. Anagnostopoulos
J. Radke

Differentiation of cerebral neoplasms with vessel size imaging (VSI)

A. Foda
E. Kellner
A. Gunawardana
X. Gao
M. Janz
A. Kufner
A.A. Khalil
R. Geran
R. Mekle
J.B. Fiebach
I. Galinovic

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma

A.S. Jacob
H. Kaul
M. Fuchs
S. Gillessen
S. Kreissl
A. Pluetschow
J. Momotow
V. Schaub
A. Huettmann
M. Haenel
A. Zimmermann
J. Dierlamm
J. Meissner
S. Mathas
S. Martin
A. Engert
M. Hallek
P. Borchmann
C. Lehmann

17. Februar 2022 in N Engl J Med

Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma

M.R. Bishop
M. Dickinson
D. Purtill
P. Barba
A. Santoro
N. Hamad
K. Kato
A. Sureda
R. Greil
C. Thieblemont
F. Morschhauser
M. Janz
I. Flinn
W. Rabitsch
Y.L. Kwong
M.J Kersten
M.C. Minnema
H. Holte
E.H.L. Chan
J. Martinez-Lopez
A.M.S. Müller
R.T. Maziarz
J.P. McGuirk
E. Bachy
S. Le Gouill
M. Dreyling
H. Harigae
D. Bond
C. Andreadis
P. McSweeney
M. Kharfan-Dabaja
S. Newsome
E. Degtyarev
R. Awasthi
C. Del Corral
G. Andreola
A. Masood
S.J. Schuster
U. Jäger
P. Borchmann
J.R. Westin

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

C. Damaschin
H. Goergen
S. Kreissl
A. Plütschow
F. Breywisch
S. Mathas
J. Meissner
M. Sökler
M.S. Topp
V. Vucinic
A. Zimmermann
B. von Tresckow
M. Fuchs
A. Engert
P. Borchmann
D.A. Eichenauer

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals

S. Denker
A. Bittner
M. Frick
J. Kase
J. Hoffmann
C. Trenker
U. Keller
C. Bogner
A. Hüttmann
J. Dürig
M. Janz
S. Mathas
R. Marks
U. Krohn
I.K. Na
L. Bullinger
C.A. Schmitt